Document is current
Any future updates will be listed below
-
Authors
Pal, Subhashis
Mittapelly, Naresh
Husain, Athar https://orcid.org/0000-0002-1086-2339
Kushwaha, Sapana
Chattopadhyay, Sourav
Kumar, Padam
Ramakrishna, Eppalapally
Kumar, Sudhir
Maurya, Rakesh
Sanyal, Sabyasachi
Gayen, Jiaur R. https://orcid.org/0000-0001-7703-9307
Mishra, Prabhat R.
Chattopadhyay, Naibedya https://orcid.org/0000-0003-2473-0246
-
Funding
Funding for this research was provided by:
Council of Scientific and Industrial Research (HCP0010)
- License Information
-
More Information
Article History
Received: 17 June 2019
Accepted: 13 December 2019
First Online: 13 January 2020
Competing interests
: Although not applicable to this study, Naibedya Chattopadhyay has received (a) consultancy fees from Glenmark Pharmaceuticals, Navi Mumbai, India, (b) consultancy fees from Glaxo Smith Kline-Consumer Healthcare, Gurgaon, India, and (c) served as an Advisory Board Member of Alkem Laboratories Ltd, India. Subhashis Pal, Naresh Mittapelly, Athar Husain, Sapana Kushwaha, Sourav Chattopadhyay, Padam Kumar, Eppalapally Ramakrishna, Sudhir Kumar, Rakesh Maurya, Sabyasachi Sanyal, Jiaur R. Gayen and Prabhat Ranjan Mishra declare that they have no financial and non-financial competing interests.
